| Health utilities and psychometric quality of life in patients with early‐and late‐stage hepatitis C virus infection PC Hsu, CA Federico, M Krajden, EM Yoshida, KE Bremner, FH Anderson, ... Journal of gastroenterology and hepatology 27 (1), 149-157, 2012 | 104 | 2012 |
| Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment? S Wieschowski, WWL Chin, C Federico, S Sievers, J Kimmelman, ... PLoS biology 16 (4), e2004879, 2018 | 79 | 2018 |
| Consider drug efficacy before first-in-human trials J Kimmelman, C Federico Nature 542 (7639), 25-27, 2017 | 68 | 2017 |
| A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib VC Henderson, N Demko, A Hakala, N MacKinnon, CA Federico, ... Elife 4, 2015 | 48 | 2015 |
| Assessment of pregabalin postapproval trials and the suggestion of efficacy for new indications: a systematic review CA Federico, T Wang, A Doussau, JS Mogil, D Fergusson, J Kimmelman JAMA internal medicine 179 (1), 90-97, 2019 | 41 | 2019 |
| Preclinical efficacy in therapeutic area guidelines from the US Food and Drug Administration and the European Medicines Agency: a cross‐sectional study H Langhof, WWL Chin, S Wieschowski, C Federico, J Kimmelman, ... British journal of pharmacology 175 (22), 4229-4238, 2018 | 28 | 2018 |
| Patient time costs and out‐of‐pocket costs in hepatitis C CA Federico, PC Hsu, M Krajden, EM Yoshida, KE Bremner, AA Weiss, ... Liver International 32 (5), 815-825, 2012 | 28 | 2012 |
| A systematic review and meta-analysis of pregabalin preclinical studies CA Federico, JS Mogil, T Ramsay, DA Fergusson, J Kimmelman Pain 161 (4), 684-693, 2020 | 22 | 2020 |
| Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval B Carlisle, CA Federico, J Kimmelman BMJ 360, k959, 2018 | 22 | 2018 |
| Reducing barriers to ethics in neuroscience J Illes, K Tairyan, CA Federico, A Tabet, GH Glover Frontiers in Human Neuroscience 4, 167, 2010 | 22 | 2010 |
| More education, less administration: reflections of neuroimagers’ attitudes to ethics through the qualitative looking glass AA Kehagia, K Tairyan, C Federico, GH Glover, J Illes Science and engineering ethics 18, 775-788, 2012 | 16 | 2012 |
| Untapped ethical resources for neurodegeneration research JM Robillard, CA Federico, K Tairyan, AJ Ivinson, J Illes BMC medical ethics 12 (1), 1-7, 2011 | 15 | 2011 |
| Ethics of Biohybrid Robotic Jellyfish Modification and Invertebrate Research N Xu, O Lenczewska, S Wieten, C Federico, J Dabiri Preprints, 2020 | 12 | 2020 |
| Not in my AI: Moral engagement and disengagement in health care AI development AA Nichol, MC Halley, CA Federico, MK Cho, PL Sankar Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 28, 496, 2023 | 9 | 2023 |
| Biomedical Data Science, Artificial Intelligence, and Ethics: Navigating Challenges in the Face of Explosive Growth CA Federico, AA Trotsyuk Annual Review of Biomedical Data Science 7, 2024 | 8 | 2024 |
| Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials CA Federico, PJ Heagerty, J Lantos, P O'Rourke, V Rahimzadeh, ... Contemporary Clinical Trials 115, 106703, 2022 | 8 | 2022 |
| Late, never or non‐existent: the inaccessibility of preclinical evidence for new drugs CA Federico, B Carlisle, J Kimmelman, DA Fergusson British journal of pharmacology 171 (18), 4247-4254, 2014 | 8 | 2014 |
| Unreliable LLM bioethics assistants: Ethical and pedagogical risks L Goetz, M Trengove, A Trotsyuk, CA Federico The American Journal of Bioethics 23 (10), 89-91, 2023 | 6 | 2023 |
| Intersecting complexities in neuroimaging and neuroethics CA Federico, S Lombera, J Illes Oxford Handbook of Neuroethics, 2011 | 6 | 2011 |
| Stronger regulation of AI in biomedicine AA Trotsyuk, CA Federico, MK Cho, RB Altman, D Magnus Science Translational Medicine 15 (713), eadi0336, 2023 | 2 | 2023 |
Jonathan KimmelmanBiomedical Ethics, McGill UniversityEmail verificata su mcgill.ca
